Proficiency testing results for metanephrines
| Variable | Year | Trial | Specimen no. | No. | Mean±standard deviation | Coefficient of variation (%) | Median | Minimum | Maximum |
|---|---|---|---|---|---|---|---|---|---|
| Metanephrines, plasma (nmol/L) | |||||||||
| Metanephrine | 2016 | 1st | CMMP-16-01 | 5 | 3.98±0.24 | 6.08 | 3.90 | 3.80 | 4.40 |
| CMMP-16-02 | 0.40±0.17 | 42.21 | 0.32 | 0.30 | 0.70 | ||||
| CMMP-16-03 | 3.71±0.34 | 9.10 | 3.63 | 3.30 | 4.10 | ||||
| 2nd | CMMP-16-04 | 5 | 0.48±0.85 | 177.02 | 0.10 | 0.10 | 2.00 | ||
| CMMP-16-05 | 6.18±0.77 | 12.50 | 6.00 | 5.50 | 7.50 | ||||
| CMMP-16-06 | 4.42±1.13 | 25.57 | 3.90 | 3.70 | 6.40 | ||||
| 2017 | 1st | CMMP-17-01 | 5 | 4.05±0.28 | 6.88 | 3.95 | 3.72 | 4.49 | |
| CMMP-17-02 | 0.53±0.29 | 55.03 | 0.43 | 0.29 | 1.10 | ||||
| CMMP-17-03 | 0.82±0.14 | 17.60 | 0.77 | 0.70 | 1.09 | ||||
| 2nd | CMMP-17-04 | 5 | 7.51±0.50 | 6.66 | 7.30 | 6.97 | 8.26 | ||
| CMMP-17-05 | 3.73±0.36 | 9.66 | 3.59 | 3.36 | 4.30 | ||||
| CMMP-17-06 | 0.22±0.13 | 58.29 | 0.21 | 0.09 | 0.47 | ||||
| Normaetanephrine | 2016 | 1st | CMMP-16-01 | 5 | 2.79±0.21 | 7.35 | 2.80 | 2.60 | 3.10 |
| CMMP-16-02 | 0.88±0.61 | 68.77 | 1.00 | 0.28 | 1.72 | ||||
| CMMP-16-03 | 2.52±0.23 | 8.94 | 2.59 | 2.21 | 2.80 | ||||
| 2nd | CMMP-16-04 | 5 | 0.80±1.32 | 157.20 | 0.30 | 0.20 | 3.20 | ||
| CMMP-16-05 | 34.70±3.52 | 10.10 | 34.20 | 30.20 | 39.90 | ||||
| CMMP-16-06 | 9.60±2.15 | 22.50 | 8.60 | 8.40 | 13.40 | ||||
| 2017 | 1st | CMMP-17-01 | 5 | 19.33±1.12 | 5.78 | 19.24 | 18.20 | 21.18 | |
| CMMP-17-02 | 1.22±0.66 | 54.23 | 1.00 | 0.51 | 2.03 | ||||
| CMMP-17-03 | 4.12±0.42 | 10.17 | 3.96 | 3.75 | 4.91 | ||||
| 2nd | CMMP-17-04 | 5 | 38.57±4.68 | 12.13 | 38.88 | 30.92 | 43.95 | ||
| CMMP-17-05 | 19.60±2.59 | 13.24 | 19.66 | 15.27 | 23.23 | ||||
| CMMP-17-06 | 0.64±0.37 | 57.81 | 0.70 | 0.23 | 1.02 | ||||
| Metanephrines, urine (ng/mL) | |||||||||
| Metanephrine | 2016 | 1st | CMU-16-01 | 7 | 543.6±49.0 | 9.0 | 548.0 | 488.4 | 615.1 |
| CMU-16-02 | 102.1±10.2 | 10.0 | 103.0 | 83.5 | 116.4 | ||||
| CMU-16-03 | 540.6±25.4 | 4.7 | 533.2 | 510.3 | 585.0 | ||||
| 2nd | CMU-16-04 | 7 | 102.9±9.9 | 9.6 | 102.0 | 90.8 | 121.3 | ||
| CMU-16-05 | 521.0±53.5 | 10.3 | 530.2 | 442.8 | 590.5 | ||||
| CMU-16-06 | 528.5±47.8 | 9.0 | 535.0 | 432.9 | 589.6 | ||||
| 2017 | 1st | CMU-17-01 | 6 | 95.4±20.1 | 21.1 | 87.8 | 70.7 | 133.8 | |
| CMU-17-02 | 558.9±42.4 | 7.6 | 553.4 | 512.8 | 617.0 | ||||
| CMU-17-03 | 542.1±79.8 | 14.7 | 571.9 | 410.3 | 630.9 | ||||
| 2nd | CMU-17-04 | 6 | 520.3±55.5 | 10.7 | 514.9 | 438.8 | 614.0 | ||
| CMU-17-05 | 525.5±47.9 | 9.1 | 515.4 | 455.6 | 604.1 | ||||
| CMU-17-06 | 104.1±10.4 | 10.0 | 101.1 | 93.0 | 124.4 | ||||
| Normaetanephrine | 2016 | 1st | CMU-16-01 | 7 | 1376.6±80.3 | 5.8 | 1,370.0 | 1,244.7 | 1,455.4 |
| CMU-16-02 | 334.5±17.0 | 5.1 | 335.0 | 302.5 | 351.5 | ||||
| CMU-16-03 | 1380.3±78.5 | 5.7 | 1,382.5 | 1,232.5 | 1,472.2 | ||||
| 2nd | CMU-16-04 | 7 | 319.8±25.9 | 8.1 | 327.1 | 281.7 | 346.1 | ||
| CMU-16-05 | 1372.7±116.4 | 8.5 | 1,402.8 | 1,141.0 | 1,499.7 | ||||
| CMU-16-06 | 1360.0±78.7 | 5.8 | 1,390.0 | 1,222.0 | 1,470.2 | ||||
| 2017 | 1st | CMU-17-01 | 6 | 250.1±36.0 | 14.4 | 251.8 | 208.4 | 317.6 | |
| CMU-17-02 | 1392.8±38.4 | 2.8 | 1,380.6 | 1,337.9 | 1,442.7 | ||||
| CMU-17-03 | 1043.0±49.3 | 4.7 | 1,054.2 | 959.4 | 1,100.8 | ||||
| 2nd | CMU-17-04 | 6 | 1222.4±107.3 | 8.8 | 1,181.5 | 1,107.0 | 1,393.9 | ||
| CMU-17-05 | 1334.5±79.7 | 6.0 | 1,326.2 | 1,229.0 | 1,475.0 | ||||
| CMU-17-06 | 328.9±30.0 | 9.1 | 322.7 | 290.0 | 389.2 |